生血宝合剂对慢性肾脏病3～5期(未透析)患者肾性贫血的影响

The Influence of Shengxuebao Mixture on Renal Anemia in Patients with Chronic Renal Disease Stage 3-5 (Undialysis)

目的:观察生血宝合剂对慢性肾脏病3～5期(未透析)患者肾性贫血的影响。方法:选择2016年3月至2017年9月在本院肾内科门诊及住院诊治的非透析肾性贫血患者120例,中医诊断为气血两虚证,随机分为对照组和观察组,每组60例。对照组给予促红细胞生成素、琥珀酸亚铁(速力菲)治疗,观察组给予生血宝合剂治疗。两组患者治疗前后分别检测血红蛋白(haemoglobin,Hb)、红细胞比容(red blood cell specific volume,HCT)、血肌酐(serum creatinine,Scr)、白蛋白(albumin,ALB)的变化情况。结果:观察组有效率90.0%,对照组有效率85.0%,两组有效率比较,差异具有统计学意义(P<0.05);治疗1个月后,对照组Hb疗效水平优于观察组(P<0.05),治疗2个月后,两组组间比较无统计学差异(P>0.05);两组治疗后HCT水平均优于治疗前(P<0.05),组间比较无统计学差异(P>0.05);治疗2个月后,观察组Scr、ALB水平优于对照组,差异具有统计学意义(P<0.05);观察组不良反应发生情况优于对照组,差异具有统计学意义(P<0.05)。结论:生血宝合剂能有效改善慢性肾脏病3～5期(未透析)患者肾性贫血症状,延缓肾损害进展,服用安全方便。

Objective:To observe the influence of Shengxuebao Mixture(SXBM) on renal anemia in patients with chronic renal disease(CKD) stages 3-5(undialysis).Methods:A total of 120 patients with non-dialysis renal anemia were selected from March 2016 to September 2017 in the outpatient and inpatient departments of Nephrology Department of our hospital.They were diagnosed as deficiency of both qi and blood by TCM,and then randomly divided into the control group and the observation group,with 60 cases in each group.The control group was treated with erythropoietin and ferrous succinate(Cerevon),while the observation group was treated with SXBM.The changes of haemoglobin(Hb),red blood cell specific volume(HCT),serum creatinine(Scr) and albumin(ALB) were detected respectively before and after the treatment in both groups.Results:The effective rate was 90.0% in the observation group and 85.0% in the control group.There was a significant difference between the two groups(P<0.05).After one month of treatment,the curative effect of Hb in the control group was better than that in the observation group(P<0.05).After two months of treatment,there was no significant difference in the curative effect of Hb between the two groups(P>0.05).After the treatment,the levels of HCT in the two groups were better than those before the treatment(P<0.05),and there was no statistical difference between the two groups(P>0.05).After two months of treatment,the levels of Scr and ALB in the observation group were better than those in the control group,and all the differences were statistically significant(P<0.05).The occurrence of adverse reactions in the observation group was better than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:SXBM can effectively improve the symptoms of renal anemia in patients with chronic kidney disease stage 3-5(without dialysis),delay the progress of renal damage,so patients can take it safely and conveniently.